Independent reporting and analysis across technology, science, startups and invention.
A US appeals court reversed a $9.15 million attorneys’ fee award against ChromaDex and Dartmouth, finding that their defense of nicotinamide-riboside supplement patents was not exceptionally meritless. The decision does not revive the invalid claims, but it draws a consequential line between losing a natural-product patent case and litigating one unreasonably.
Read story
After a record $6.3 billion theft, Binance says it used emergency reserves, an insurance fund and corporate money to replace most affected assets. The remaining tokens are less liquid, withdrawals are still suspended, and the complete cryptographic reserve proof is not due until Tuesday.
Read story
OpenAI, Google, Microsoft and Anthropic are converging on one machine-readable signal for generative-AI training preferences. The proposal could simplify publisher controls, but it is not yet an IETF standard, does not block crawling or grounding by itself, and creates no licensing or payment right.
Read story
A WIPO Secretariat report gives patent offices a menu of choices for proving human contribution, handling AI-generated disclosures and deciding when routine access to AI makes an invention obvious. The options now go before member states; they are not new global rules.
Read story
The appeals court reversed an order compelling a patent buyer’s unredacted purchase agreement after Europe’s Unified Patent Court had rejected the same evidence request as premature. The ruling limits, but does not eliminate, U.S. discovery assistance for foreign patent cases.
Read story
Project Suncatcher has completed an end-to-end inference test in orbit, returning a short response as the spacecraft passed Svalbard. The milestone proves a data-centre-class accelerator can execute a model in space, but not that orbital AI infrastructure is yet practical.
Read story
A new destination-level analysis finds that exported solar panels, batteries, wind turbines and electric vehicles could cut annual emissions outside China by nearly 2%. The estimate is consequential—but it is a projection, not a measured global inventory.
Read story
The trillion-parameter model can now run on private infrastructure and reproduce real software flaws before patching them. Mistral says its safeguards distinguish defensive from malicious work, but downloadable weights cannot be recalled or centrally monitored.
Read story
The agreement would close a decade-old antitrust fight over insulin-pen patents listed in the FDA’s Orange Book. A court had already called the listings improper and exclusionary, but causation, Sanofi’s defense and damages remained unresolved.
Read story